JNJ-16241199
Product Specifications
UNSPSC Description
JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases
the expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study[1].
Target Antigen
Apoptosis; HDAC
Type
Reference compound
Related Pathways
Apoptosis;Cell Cycle/DNA Damage;Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jnj-16241199.html
Solubility
10 mM in DMSO
Smiles
O=S(N(CC1)CCN1C2=NC=C(C(NO)=O)C=N2)(C3=CC=C4C(C=CC=C4)=C3)=O
Molecular Weight
413.45
References & Citations
[1]Arts J, et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer. 2007;97(10):1344-1353.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-10226/JNJ-16241199-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-10226/
Clinical Information
Phase 1
CAS Number
604769-01-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7080045 Inquire
Recombinant Eucalyptus globulus subsp. globulus Photosystem II CP43 chlorophyll apoprotein (psbC), partial
Ask
View Details